Last reviewed · How we verify
Direct renin inhibitor
A direct renin inhibitor blocks the enzyme renin, preventing the initial step of the renin-angiotensin-aldosterone system (RAAS) and reducing blood pressure.
A direct renin inhibitor blocks the enzyme renin, preventing the initial step of the renin-angiotensin-aldosterone system (RAAS) and reducing blood pressure. Used for Hypertension.
At a glance
| Generic name | Direct renin inhibitor |
|---|---|
| Also known as | no other drug as RAS inhibitor |
| Sponsor | Medical Practice Prof D. Ivanov |
| Drug class | Direct renin inhibitor |
| Target | Renin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Renin catalyzes the conversion of angiotensinogen to angiotensin I, the first and rate-limiting step of the RAAS cascade. By directly inhibiting renin at its active site, this drug prevents downstream generation of angiotensin II, a potent vasoconstrictor and aldosterone stimulator. This results in vasodilation, reduced sodium retention, and lower blood pressure.
Approved indications
- Hypertension
Common side effects
- Hyperkalemia
- Diarrhea
- Dizziness
- Fatigue
Key clinical trials
- ARB, ACEi, DRi Effects on COVID-19 Course Disease
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Shiga Microalbuminuria Reduction Trial-2 (PHASE4)
- Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects (PHASE4)
- Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF. (PHASE3)
- Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany
- Influence of Aliskiren on Albuminuria After Kidney Transplantation (NA)
- Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Direct renin inhibitor CI brief — competitive landscape report
- Direct renin inhibitor updates RSS · CI watch RSS
- Medical Practice Prof D. Ivanov portfolio CI